Biochemical monitoring of vasoactive peptides during angiotensin converting enzyme inhibition.
We present a brief survey of changes in vasoactive peptide systems during therapy with angiotensin converting enzyme inhibitors. Particular attention is paid to several methodological problems which are relevant to the clinical biochemistry and physiology of patients treated with this new type of drug.
D000803:Angiotensin I / Q000097:blood; D000804:Angiotensin II / Q000097:blood; D000806:Angiotensin-Converting Enzyme Inhibitors; D001920:Bradykinin / Q000097:blood; D002216:Captopril / Q000627:therapeutic use*; D003429:Cross Reactions; D004359:Drug Therapy, Combination; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use*; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy; D007700:Kinetics; D007703:Peptidyl-Dipeptidase A / Q000097:blood; D011863:Radioimmunoassay / Q000379:methods; D012083:Renin / Q000097:blood*
D000806:Angiotensin-Converting Enzyme Inhibitors; D006852:Hydrochlorothiazide; D000804:Angiotensin II; D000803:Angiotensin I; D002216:Captopril; D007703:Peptidyl-Dipeptidase A; D012083:Renin; D001920:Bradykinin